





(Under the argis of Indian Association of Medical Microbiologists) P1 Unit, Department of Clinical Virology, Christian Medical College, Vellore-632004, Tamil Nadu

Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

15th SEROLOGY CMCVIROEQAS EVALUATION FINAL REPORT

PANEL: BBVS

CMCVIROEQAS ID.

V0283

Opening Date: 01-11-2021

Result Receiving Date: 12/11/2021

Distribution No:

	1	ntended Resu	t .	Your Result				
Specimen#	HIV HBsAş		HCV	IIIV	HBsAg	HCV		
50132109	Negative	Negative	Negative	NEGATIVE	NEGATIVE	NEGATIVE		
50132110	Negative	Negative	Positive	NEGATIVE	NEGATIVE	POSITIVE		
50132111	Positive	Negative	Negative	POSITIVE	NEGATIVE	NEGATIVI		
50132112	Negative	Negative	Negative	NEGATIVE	NEGATIVE	NEGATIVE		
Your Score	-	,	- 1 × 2 ×	8/8 (100%)	8/8 (100%)	8/8 (100%)		

Scoring System

Qualitative Results	Score
Concordant Result	7
Intermediate/Indeterminate	1
Discordant Result	U

Page 1 of 6

PT Unit, Department of Clinical Virology CHRISTIAN MEDICAL COLLEGE, VELLORI:

Incharge

Dr.Nikhil S.Deshpande

Associate Professor Department of Pathology Dr.Balasaheb Vikhe Pucil Rural Medical College Loni

P. . . (00), Loni BK, 413736

Dr.S.N.JANGLE

CCI.- Biochemistry Prof. & H.O.D. Biochemistry Rural Medical College, PMT PMT, RMC, Loni Tal. Rahata, Dist. A'Nagar-413736







PC - 1034

CMCVIROEQAS

(Under the aegis of Indian Association of Medical Microbiologists) PT Unit, Department of Clinical Virology, Christian Medical College, Vellore-632004, Tamil Nadu

Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

Cumulative Report of this cycle:

Total Number of specimens you received

Number of markers reported as not examined

Specimen # not used for analysis

0

Number of Specimens Reported Late for analysis :

Your cumulative score for the specimens you reported:

24 out of the possible total of 24

Total Number of participants for BBVS

: 536

Total Number of Participants who turned in their results : 505

Standard Deviation Index (SDI)

it in the	HIV Ag/Ab	HBsAg	HCV-Ab	
Performance of the participating Laboratories				
Mean score of all Laboratories	8.0	8.0	8.0	
Standard Deviation	0.3	0.1	0.2	
Your Laboratory SDI	0	0	0	

SDI of \pm 3 and above indicates possible poor performance





CMCVIROEQAS


PC 1034

(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.ln Phone: 0416-2283455
Participants who reported all analyzed specimens accurately

Marker	Number of Participants with all four specimen's results	Percentage of Participants with concordant result from all four specimens
HIV	499	98.4
HBsAg	503	99.6
HCV-Ab	500	99.4

Performance Graph

BBVS - HIV Ag/Ab








PC 1034

CMCVIROEQAS


(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu

Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

BBVS - HBsAg



BBVS - HCV Ab



Page 4 of 6

PT Unit, Department of Clinical Virology CHRISTIAN MEDICAL COLLEGE, VELL, ORE







CMCVIROEOAS

(Under the aegis of Indian Association of Medical Microbiologists)
PT Unit, Department of Clinical Virology, Christian Medical College,
Vellore-632004, Tamil Nadu
Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

V-1 (1503)	IIIV Ag/Ab		11	BsAg	HCV-Ab		
	n	Discordant	- 11	Discordant	11	Discordan	
Chemiluminescence	229	2 (0.9%)	219	0	224	1 (0.4%)	
ELFA	11	1 (9.1%)	. 1.1 -	()	13	0	
ELISA	77	1 (1.3%)	75	0	78	2 (2.6%)	
Rapid Assay	182	4 (2.2%)	198	2 (1.0%)	185	0	
Not Done	6	1 2	2		5	-	

Comments:

This PT program is a simultaneous and continuous scheme. Participants are scored based on qualitative result. If more than 30% of the laboratory report discrepant result that sample will not be considered for analysis.

Confidentiality of the results:

The results are kept confidential between the participant and the provider. The results can be revealed to a regulatory body with written consent from the participant. However, in exceptional circumstances, results from a particular participant will be provided to the regulatory body and the participant will be notified of this action in writing.





PC 10.34

CMCVIROEQAS

(Under the aegis of Indian Association of Medical Microbiologists) PT Unit, Department of Clinical Virology, Christian Medical College, Vellore-632004, Tamil Nadu Email: viroeqas@cmcvellore.ac.in Phone: 0416-2283455

Assigned Value:

Assigned value is determined using multiple assays/multiple testing of the same analyte. The proficiency testing material is a pooled lyophilized plasma sample prepared by following institutional proficiency testing standard operating protocol (PT-SOP) by trained staff. None of the work related to testing, preparation and packaging of sample is subcontracted. The homogeneity of the PT material is determined using multiple testing. The stability of the testing material is determined by assessing the reactivity of the specimen till the closing date. The homogeneity and stability of the materials were found satisfactory as per ISO13528:2015.

Standard Deviation Index (SDI):

Standard deviation index is used to analyze your laboratories performance relative to the other participating laboratories. The SDI is calculated for each parameter or marker separately using the formula

SDI = (Your score - interlaboratory mean score)/interlaboratory standard deviation of the score

Enquiries: For queries, please contact CMCVIROEQAS coordinator at the email viroequas(acmevellore.ac.in) For all communications, please use your CMCVIROEQAS LAB ID and Distribution Number.

Name of CMCVIROEQAS Coordinator

Signature

Dr. Rajesh Kannangai

Department of Clinical Virology

Report Dispatch Date: 28-12-2021

Report authorized by: CMCVIROEQAS Coordinator

END OF REPORT

Page 6 of 6

PT Unit, Department of Clinical Virology CHRISTIAN MEDICAL COLLEGE, VELLORE



A

109th IAMM EQAS Microbiology: Bacteriology/ Serology
CMC MICRO EQAS

Department of Clinical Microbiology, Christian Medical College, Vellore-632004, Tamil Nadu
Email: eqas@cmcvellore.ac.in, Twitter: @microeqas, Phone: +91-416-2282588



OCTOBER 2021

109th EQAS EVALUATION REPORT

MEMBER ID: M 0 3

Marks Obtained: 69.5/71 (97.9%)

OCTOBER 2021 / BACTERIOLOGY SMEARS

Question: Carry out the appropriate staining procedure and document the relevant observation.
Provide the Impression or probable organism seen (AS ASKED)
Please refer the attached evaluation format/answer template for details on the criteria for evaluation.

PLEASE NOTE: The inaccuracies in the participant report resulting in deduction of marks has been <u>underlined</u> in the expected smear report.

Number SM1	Question Question Please carry out a Gram stain	Appete Report 1	1 E	valuatio	n.
	on the given fixed smear prepared from a BLOOD culture specimen obtained from a 74-year-old gentleman	Description of Organism/s (2marks). Many Gram-positive spherical/oval cocci (1) arranged in pairs, long and short chains (1) Probable organism (1 mark): Streptococcus spp/ Enterococcus spp (1)	0	0.5	1
	presenting with high grade fever and chills following prostrate surgery (TURP).	Where can the blood culture specimen be stored if there is a delay in transport? (I mark): Ideally Incubator / room-temperature (1)	1.5	2	2.5
		What is the upper limit of storing the specimen outside of these conditions? (No marks allotted): As mentioned by the manufacturer	3	3.5	(1)

Page 1 of 6

SM2	Please carry out a Gram stain on the given fixed smear prepared from an isolate from a THROAT swab received from a 2-year-old girl who has not received her routine	Description of Organism/s (2marks): Many Gram-positive bacilli (1) club-shaped in X and V / cunciform arrangements (1) Probable organism (1 mark): Corynebacterium diphtheriae	0	0.5	1
	vaccinations in the last 2 years. She presented with fever, sore throat, bilateral facial swelling with stridor.	What precaution are to be taken in the lab while handling the specimen (Imark) [a] Specimen handling following standard precautions in a BSC Type 2 A2 [b] Personnel should be adequately vaccinated and have a minimal of diphtheria antibody level of at least 0.1 PU/ml.	1.5	2	2.5
	*	[c] If unvaccinated and exposed should begin antimicrobial prophylaxis if specimen is culture or PCR positive	3	3.5	0
SMB	Please carry out a Gram stain	Please shade all the boxes that are relevant to your findings:			
	on the given fixed smear prepared from a URINE specimen of a 22-year-old pregnant patient in her third trimester with a history of increased frequency of micturition for 2 days.	Pus cells: Many Moderate Few Occasional None (0.5 mark) Organism burden: Many Moderate Few Occasional None	0	0.5	1
		✓ Gram positive cocci in pairs, chains and clusters (0.25) ✓ Gram positive bacilli (0.5) ✓ Gram negative bacilli (0.25) ✓ Gram negative coccobacilli (0.5) ✓ Gram positive budding yeast like organisms (0.5)	1.5	2	2.5
	\(\frac{1}{2} = \frac{1}{2} =	Impression/ Comments regarding the specimen: Improperly collected specimen (0.5 mark) What recommendation may be advised by the lab?: Suggest repeat appropriately collected mid-stream clean catch specimen (0.5 mark)	3	3.5)	4

Page 2 of 5

OCTOBER 2021 / BACTERIOLOGY CULTURE:

Question: A freeze-dried (hophilized) culture of an organism isolated from a clinical specimen is given. Carry out the appropriate techniques exercise and identify the pathogen. Carry out the antimicrobial susceptibility testing according to the panel given below.

Please refer the attached evaluation format for details on the criteria for evaluation.

A 'partially correct' or 'incorrect' component of the participant report which has resulted in a deduction of marks has been in indicated in the evaluation report below.

"REMOVED FROM EVALUATION" refers to a test that has not been evaluated for ALL participants. The explanation can be found in the EQAS statistics and the EQAS explained documents.

CONTROL (LONG) (CONTROL (LONG) (CONTROL (LONG) (CONTROL (LONG)) (CONTROL (
--

dentification details dicroscopy (Gram stain + Mutility)	Reported	Not reported	Evaluation (7 marks)
alient out	1		0 0.5 (1)
alient culture and biochemical findings enabling flual certification (Minimum 3 key characteristics)			1 2 3 1
nal identification	/	•	0.5 1 1.5(2)

Susceptibility report	EXPECTED REPORT			PARTICIPAN	T REPORT	MARK	TYPE OF ERROR	
(6)	Zone size (mm)	MIC (µg/ml)	Interpretation	Correct	Incorrect	10 marks	Error	
Cefoxitin 30pg	≥ 22	≤4	Susceptible	7		-1 0 1 2	mE/ ME/ VME	
Chloramphenicol 30µg	≥18	≤8	Susceptible	7		-1 0 1 (2)	mE/ ME/ VME	
Co-trimoxazole 1.25/23.75µg	≥16	≤2/38	Susceptible	REMOVED FROM EVALUATION				
Linezolid 30µg	≥21	≤4	Susceptible	1		-1 0 1 (2)	mE/ ME/ VME	
Erythromycin 15µg	≤13	≥8	Resistant	1		-1 0 1 (2)	mE/ ME/ VME	
Clindamycin 2µg	D-test PO	SITIVE	Resistant	7		-1 0 1 (2)	mE/ ME/ VME	



GON Collici Crom - TESTIDINO PENASCENCIA CONTROLLA CONTR

Identification details	Reported	Not reported	Evaluation (7 marks)	
Microscopy (Gram stain + Motility)	-		0 0.5 (1)	
Salient culture and biochemical findings enabling final identification (Minimum 3 key characteristics)	*		1 2 3 4	
Final identification	/ .		0.5 1 1.5 (2)	

Susceptibility		EXPECTED	REPORT	PARTICIPANT REPORT		MARK	TYPE OF ERROR	
report	Zone size (mm)	MIC (μg/ml)	Interpretation CLSI	Correct	Incorrect	10 marks	Егтог	
Ceftazidime 30µg	≤17	≥16	Resistant		Ezypus I	-1 0 1 2	mE/ ME/ VME	
Cestriaxone 30µg	≤19	≥4	Resistant	. 1		-1 0 1 2	mE/ ME/ VME	
Co-trimox220le 1.25/23.75µg	≤10	≥4/76	Resistant	1	The second	-1 0 1 2	mE/ ME/ VME	
Levofloxacin 5µg	. 516	≥2	Resistant	1	* 184	-1 0 1 2	mE/ ME/ VME	
Gentamicio 10µg	_≤12	≥16	Resistant	✓ A.	100	-1 0 1(2)	mE/ME/VME	

CU3. Isolated from a FAECES specimen of a 6-year-old boy with a 2-day history of abdominal pain and frequent passage of scanty stools with mucous and blood.

FINAL IDENTIFICATION: Shigella flexmeri semiype 1

licroscopy (Gram stain + Motility)	Reported	Not reported	Evaluation (7 marks)
alient culture and biochemical findings enabling final	1		0 0.5 (1)
dentification (Minimum 3 key characteristics)	1		1 2 3 4
	/		05 1 15(2)

Susceptibility report	1	EXPECTED R	EPORT	PARTICIPA	NT REPORT	MARK	TYPE OF ERROR	
Americans	Zone size (mm)	MIC (µg/ml)	Interpretation	Correct	Incorrect	12 marks	Error	
Ampicillin 10µg	≤13	≥32	Resistant	1		-1 0 1(2)	mE/ ME/ VME	
Cefotaxime 30µg	522	≥4	Resistant	-		-1 0(1) 2	(mE) ME VME	
Co-trimoxazole 1.25/23.75µg	≥16	≤2/38	Susceptible	7		-1 0 1 2	mE/ ME/ VME	
Ciprofloxacio 5µg	⊴1	≥1	Resistant		ideal v	-1 0 1(2)	mE/ME/VME	
Azithromycin 15µg	≥16	_≤8	Susceptible	- · ·	200	-1 0 1(2)	mE/ME/VME	
Meropenem 10µg	≥23	≤1	Susceptible	1		-1010	mE/ME/VME	

OCTOBER 2021 / SEROLOGY
Please refer the attached evaluation format/answer template for details on the criteria for

Par	ameter	Your Interp		or dealis on	The same of the	ed Result	2. 15 36 30	#1. V.
9*03		Согтест	Incorrect	sto 👬	STH .	Interpretation	Max Marks	Your Score
 SE1	Widal*	1.		Negative	Negative	Not Suggestive of Enteric Fever / Typhoid Fever	2	2

*Expected value is determined by the Proficiency Testing Provider (PTP).

SE2 ASO Negative 200 IU/mL Negative Latex Agglutination (n-450) Not Applicable			Result	Your Value	Intended Result	Method	Robust	Robust	Range	Z&Z'	Max	Your
SE3 CRP Positive at Later Application	SE2	ASO	Negative	<200 IU/mL	.00			score		Marks	Score	
Positive Positive (n-220) 34.0754 21.1902 6 to 192 -0.5	SE3	CRP	Positive	24 mg/L	Positive	Latex Agglutination	34.0754			46	2	1

Disclaimer:

This is a confidential document and subject to the rules of confidentiality as described by the ISO 17043:2010 standard.

MEMBER ID: M 0 3 7 2

SM1	SM2	SM3	CU1	CU2	CU3	SE1	SE2	SE3	Marks	obtained
4	4	3.5	17	17	18	2	2	2	69.5	97.9%
4-1	4	4	17	17	19	2	2	.2	Maximun	1 marks = 71

- ou or mind Dr. Rani Diana Sahni Scientific Co-ordinator

Report Dispatch Date: 15.03.2022

Dr. John A Jude Prakash Quality Manager

v. sorair Dr. V. Balaji PT Co-ordinator

End of Report

Page 6 of 6







JUNE 2021

108th EQAS EVALUATION REPORT

MEMBER ID:

Marks Obtained: 70.5/71 (99.3%)

JUNE 2021 / BACTERIOLOGY SMEARS

Question: Carry out the appropriate staining procedure and document the relevant observation.

Provide the Impression or probable organism seen (AS ASKED)

Please refer the attached evaluation format/answer template for details on the criteria for evaluation.

PLEASE NOTE: The inaccuracies in the participant report resulting in deduction of marks has been underlined in the expected report.

Exercise Number	Question	Expected Report	Evaluation				
SMI	Please carry out a Gram stain on the given fixed smear prepared from a	Presence of host cells & debris (Imark): Many pus cells	0	0.5	1		
	CSF specimen obtained from a 3-year old child presenting at a rural hospital facility with high grade fever and	Description of Organism/s (2marks): Many (0.5) pleomorphic (0.5) Gram negative bacilli (1)	1.5	2	2.5		
	ultered sensorium. Mother has defaulted on child's vaccinations.	Probable organism (1 mark): Hemophilus spp	3	3.5	(1)		
SM2	Please carry out a Gram stain on the given fixed smear prepared from an	Presence of host cells & debris (1mark): Moderate pus cells	0	0.5	1		
4(₂ x	endotracheal aspirate of a 43-year old man admitted in ICU for 5 days with SARS-CoV2.	Description of Organism/s (2marks): Many (0.5) Gram negative (1) cocco-bacilli (0.5)	1.5	- 2	2.5		
	SARS-C072.	Probable organism (1 mark): Acinetobacter spp	3	3.5	(1)		

Page 1 of 6

NB .	Please carry out a Gram stain on the given flated smear prepared from a sputum specimen of an \$2-year old COVID-negative gentleman seen in casualty with fever and breathlessness.	Pus cells: Oceasional Epithelial cells: Many ✓ Gram positive cocci in clusters ✓ Gram positive cocci in pairs and chains	0	0.5	. <u>;</u> "
		Grum positive bacilli in palisade arrangement Gram negative cocci in pairs and clusters Gram negative bacilli x State and a grand grand grand	1.5	2	2.5
		Impression/ Comments (1 mark): Excessive salivary contamination. Improperly collected sputum specimen. Name the grading system you used to grade the sputum specimen: not graded	3	3.5	4

JUNE 2021 / BACTERIOLOGY CULTURE:

Question: A freeze-dried (lyophilized) culture of an organism isolated from a cilinical specimen is given. Carry out the appropriate techniques for each exercise and identify the pathogen. Carry out the antimicrobial susceptibility testing according to the panel given

Please refer the attached evaluation format for details on the criteria for evaluation.

A 'partially correct' or 'incorrect' component of the participant report which has resulted in a deduction of marks has been in indicated in the evaluation report below.

"REMOVED FROM EVALUATION" refers to a test that has not been evaluated for all participants. The explanation can be found in the EQAS statistics and the EQAS explained documents.

CU 1: Isolated from a URINE specimen of a 63-year-old patient with recurrent urinary tract infections.
FINAL INDENTIFICATION: Enterocrecus faccalis

Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	V		0 0.5 (1)
Sallent culture and biochemical findings enabling final identification (Minimum 3 key characteristics)			1 2 3 4
Final identification	V	T. 1	0.5 1 1.5 (2)

Susceptibility report	EX	PECTED R	EPORT	PARTICIPAN	NT REPORT	MARK	TYPE OF ERROR	
	Zone size (mm)	MIC (µg/ml)	Interpretation	Correct	Incorrect	12 marks	Error	
Ampicillin 10µg	≥17	≤8	Susceptible	V		-1 0 1 2	mE/ ME/ VME	
High Level gentamicin 120µg	=6	>500	RESISTANT	*	; .	-1 0 1 🔾	mE/ NE/ VME	
Nitrofurantoin 300µg	≥17	≤32	Susceptible	1		-1 0 1(2)	mE/ ME/ VME	
Vancomycin 30µg	≥17	≤4	Susceptible	· ·	- 19-1	-1 0 1(2)	mE/ ME/ VME	
Teicoplanin 30µg	≥14	≤8	Susceptible	· /		-1 0 1(2)	mE/ ME/ VME	
Linezolid 30µg	≥23	≤2	Susceptible	1		-1 0 1(2)	mE/ ME/ VNIE	

CU2: Isolated from a SPUTUM specimen of a 45-year man admitted in ICU with Ventilator associated pneumonia.

FINAL IDENTIFICATION: Pseudomonas aeruginosa

Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	7.		0 0.5 (1)
Salient culture and biochemical findings enabling final identification (Minimum 3 key characteristics)	-		1 2 3 1
Final identification	-		0 0.5 1 1.5 (2)

Susceptibility		EXPECTED	REPORT	PARTICIPAN	NT REPORT	MARK	TYPE OF ERROR	
report	Zone slze (mm)	MIC (µg/ml)	Interpretation CLSI	Correct	Incorrect	10 marks	Error	
Ceftazidime 30µg	≥18	. ≤8	Susceptible	1		-1 0 1 2	mE/ME/VME	
Levofloxacin 5µg	≤14	. ≥1	RESISTANT	1	1	-1 0 1 (2)	mE/ME/VNE	
Amikacin 30µg	≥17	≤16	Susceptible	1	70.0	-1 0 1 (2)	mE/ ME/ VME	
Piperacillin- Tazobactam 100/10µg	≥21	≤16/4	Susceptible	- 1	REMOVED	FROM EVALUA	ATION	
Imipenem10µg	≤15	. ≥8	RESISTANT	1		-1 0 1 (2)	mE/ ME/ VIE	
Meropenem 10µg	≤15	≥3	RESISTANT	1		-1 0 1 (2)	mE/ ME/ VME	

CU3: Isolated from a BLOOD culture specimen of a 72-year old gentleman in renal failure with urosepsis.

FINAL IDENTIFICATION: Escherichia coli

Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	1		0 0.5 1
Salient culture and biochemical findings enabling final identification (Minimum 3 key characteristics)	1		1 2 3 4
i (au) (Generation	7	,	0 0.5 1 1.5 (2)

Sesteptibility	E	XPECTED	REPORT	PARTICIPA	ANT REPORT	MARK	TYPE OF ERROR
report	Zone size	MIC (μg/ml)	Interpretation CLSI	Correct	Incorrect	10 marks	Error
Cefotaxime 30µg	22	≥4	Resistant	1		-1 0 1 (2)	mE/ ME/ VME
Cestazidime 30µg	≤17	≥16	Resistant	1		-1 0 1 2	mE/ME/VME
Amikacin 30µg	≤14	≥64	Resistant	√		-1 0 1 (2)	mE/ ME/ VME
Piperacillin- Tazobactam 100/10µg	≤17	≥128/4	Resistant	1	413	-1 0 1 (2)	mE/ ME/ VME
Minocycline 30µg	≥16	≤4	SUSCEPTIBLE	1	REMOVED F	ROM EVALUA	TION
Meropenem 10µg	≤19	≥4	Resistant	1	88	-1 0 1 2	mE/ ME/ VME

Page 5 of 6

JUNE 2021 SEROLOGY

·Fic.	se refer the ar	teched evalu	ation format/an	swer template	for details on the c	riteria for	evaluatio	n.	· ·		11-11
	l p	Your	Your Value	Intended	Method	Robust	Robust	Range	Z & Z'	Max	Your Score
	Parameter	Result		Result		Mean	SD		- score	Marks	Score
SE1	RA	Negative	Not	Negative	Lates Agglutination	ŇA	NA	NA.	NA .	2	2
SLI	, AC	regative	Reported	regative	(n-389)	1.7					-
SE2	CRP	Positive	24 mg/L	Positive	Latex Application	32.2239	19.8230	6 to 192	0,4	2	. 2

NA: Not Applicable

	Parameter	Your Result	Intended result	correct	Incorrect	Max Marks	Your		
	RPRADRL	Nou-Reactive	Non-Reactive	✓	9	2	2		
SE3	TPHA	3 13							
	Syphilis			NOT DO	NE				

Disclaimer:

This is a confidential document and subject to the rules of confidentiality as described by the ISO 17043:2010 standard.

ME	MEER ID	M 0	3 7 2								
	SMI	SM2	SM3	CU1	CU2	CU3	SE1	SE2	SE3	Marks	oblained
	4	4	3.5	19	17	- 17	2	2	2	70.5	99.3%
	;	4	4	19	17	17	2.	2	2	Maximun	n marks = 71

		Co.
Dr. Rani Diaza Sahoi Sciestific Co-ordinatur	Dr. John A Jude Prakash Quality Manager	Dr. V. Balaji PT Co-ordinator
Report Dispatch Date: 20.10 2021		

Page 6 of 6